Antioxidants: Positive or negative actors?

Biomolecules

Volumn 8, Issue 4, 2018, Pages

  Salehi, Bahare ^a,b   Martorell, Miquel ^c   Arbiser, Jack L ^d   Sureda, Antoni ^e   Martins, Natália ^f,g   Maurya, Pawan Kumar ^h   Sharifi Rad, Mehdi ⁱ   Kumar, Pradeep ^j   Sharifi Rad, Javad ^b,k  

^a Shahid Beheshti University of Medical Sciences   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF CONCEPCIÓN   (Chile)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^f University of Porto   (Portugal)

^g UNIVERSITY OF PORTO   (Portugal)

^h AMITY UNIVERSITY   (India)

ⁱ ZABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^j NORTH EASTERN REGIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY   (India)

^k UNIVERSITY OF WINNIPEG   (Canada)

more..

Author keywords

Antioxidants; Cancer; Inflammation; Natural products; Reactive species

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIVITAMIN; OXYGEN RADICAL; REACTIVE OXYGEN METABOLITE; RETINOL; TRANSCRIPTION FACTOR NRF2;

ALCOHOL ABSTINENCE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR MORTALITY; CELL AGING; CELL SURVIVAL; CYTOKINE RELEASE; DIETARY INTAKE; DISORDERS OF ACID BASE BALANCE; DNA REPAIR; EXERCISE; HIP FRACTURE; HOMEOSTASIS; HORMESIS; INFLAMMATION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NUTRITIONAL DEFICIENCY; OSTEOLYSIS; OSTEOPOROSIS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; SMOKING CESSATION; TERATOGENESIS; TUMOR GROWTH; VITAMIN SUPPLEMENTATION; ANIMAL; DRUG EFFECT; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; CARCINOGENESIS; HUMANS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 85055616556     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom8040124     Document Type: Review

References (64)

1. Jones, D.P. Redefining oxidative stress. Antioxid. Redox Signal. 2006, 8, 1865–1879. [CrossRef] [PubMed]
2. Baineni, R.; Gulati, R.; Delhi, C.K. Vitamin A toxicity presenting as bone pain. Arch. Dis. Child. 2016, 102, 556–558. [CrossRef] [PubMed]
3. Pawar, R.K.; Bhagure, G.R.; Chavan, R.P. Antioxidants and their role in nurture human life and industry: A review. Int. J. Chem. Stud. 2016, 4, 22–26.
4. Maes, M.; Bonifacio, K.L.; Morelli, N.R.; Vargas, H.O.; Barbosa, D.S.; Carvalho, A.F.; Nunes, S.O.V. Major differences in neurooxidative and neuronitrosative stress pathways between major depressive disorder and types i and ii bipolar disorder. Mol. Neurobiol. 2018, 55, 1–16. [CrossRef] [PubMed]
5. Shirley, R.; Ord, E.N.J.; Work, L.M. Oxidative Stress and the Use of Antioxidants in Stroke. Antioxidants 2014, 3, 472–501. [CrossRef] [PubMed]
6. Kumar, P.; Chand, S.; Maurya, P.K. Quercetin-modulated erythrocyte membrane sodium-hydrogen exchanger during human aging: Correlation with atpase’s. Arch. Physiol. Biochem. 2016, 122, 141–147. [CrossRef] [PubMed]
7. Patrice, T.; Rozec, B.; Sidoroff, A.; Blanloeil, Y.; Despins, P.; Perrigaud, C. Influence of vitamins on secondary reactive oxygenspecies production in sera of patients with resectable NSCLC. Diseases 2016, 4, 25. [CrossRef] [PubMed]
8. Halliwell, B.; Gutteridge, J.M. The antioxidants of human extracellular fluids. Arch. Biochem. Biophys. 1990, 280, 1–8. [CrossRef]
9. Mut-Salud, N.; Álvarez, P.J.; Garrido, J.M.; Carrasco, E.; Aránega, A.; Rodríguez-Serrano, F. Antioxidant intake and antitumor therapy: Toward nutritional recommendations for optimal results. Oxid. Med. Cell. Longev. 2016, 2016, 6719534. [CrossRef] [PubMed]
10. Lawenda, B.D.; Kelly, K.M.; Ladas, E.J.; Sagar, S.M.; Vickers, A.; Blumberg, J.B. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J. Natl. Cancer Inst. 2008, 100, 773–783. [CrossRef] [PubMed]
11. Hekimi, S.; Lapointe, J.; Wen, Y. Taking a “good” look at free radicals in the aging process. Trends Cell Biol. 2011, 21, 569–576. [CrossRef] [PubMed]
12. Halliwell, B. The antioxidant paradox: Less paradoxical now? Br. J. Clin. Pharmacol. 2013, 75, 637–644. [CrossRef] [PubMed]
13. Larrosa, M.; González-Sarrías, A.; García-Conesa, M.T.; Tomás-Barberán, F.A.; Espín, J.C. Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. J. Agric. Food Chem. 2006, 54, 1611–1620. [CrossRef] [PubMed]
14. González-Sarrías, A.; Giménez-Bastida, J.A.; García-Conesa, M.T.; Gómez-Sánchez, M.B.; García-Talavera, N.V.; Gil-Izquierdo, A.; Sánchez-Álvarez, C.; Fontana-Compiano, L.O.; Morga-Egea, J.P.; Pastor-Quirante, F.A. Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. Mol. Nutr. Food Res. 2010, 54, 311–322. [CrossRef] [PubMed]
15. Cerimele, F.; Battle, T.; Lynch, R.; Frank, D.A.; Murad, E.; Cohen, C.; Macaron, N.; Sixbey, J.; Smith, K.; Watnick, R.S. Reactive oxygen signaling and MAPK activation distinguish epstein–barr virus (EBV)-positive versus EBV-negative burkitt’s lymphoma. Proc. Natl. Acad. Sci. USA 2005, 102, 175–179. [CrossRef] [PubMed]
16. Czernichow, S.; Vergnaud, A.C.; Galan, P.; Arnaud, J.; Favier, A.; Faure, H.; Huxley, R.; Hercberg, S.; Ahluwalia, N. Effects of long-term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic syndrome in adults. Am. J. Clin. Nutr. 2009, 90, 329–335. [CrossRef] [PubMed]
17. Park, Y.; Spiegelman, D.; Hunter, D.J.; Albanes, D.; Bergkvist, L.; Buring, J.E.; Freudenheim, J.L.; Giovannucci, E.; Goldbohm, R.A.; Harnack, L.; et al. Intakes of vitamins A, C, and E and use of multiple vitamin supplements and risk of colon cancer: A pooled analysis of prospective cohort studies. Cancer Causes Control 2010, 21, 745–757. [CrossRef] [PubMed]
18. Hercberg, S.; Galan, P.; Preziosi, P.; Bertrais, S.; Mennen, L.; Malvy, D.; Roussel, A.M.; Favier, A.; Briançon, S. The SU.VI.MAX Study: A randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch. Intern. Med. 2004, 164, 2335–2342. [CrossRef] [PubMed]
19. Rothman, K.J.; Moore, L.L.; Singer, M.R.; Nguyen, U.-S.D.; Mannino, S.; Milunsky, A. Teratogenicity of high vitamin A intake. N. Engl. J. Med. 1995, 333, 1369–1373. [CrossRef] [PubMed]
20. Stargrove, M.B.; Treasure, J.; McKee, D.L. Herb, Nutrient, and Drug Interactions: Clinical Implications and Therapeutic Strategies; Elsevier Health Sciences: Amsterdam, The Netherlands, 2008.
21. Biesalski, H.K. Comparative assessment of the toxicology of vitamin A and retinoids in man. Toxicology 1989, 57, 117–161. [CrossRef]
22. Azaïs-Braesco, V.; Pascal, G. Vitamin A in pregnancy: Requirements and safety limits. Am. J. Clin. Nutr. 2000, 71, 1325S–1333S. [CrossRef] [PubMed]
23. Cartmel, B.; Moon, T.E.; Levine, N. Effects of long-term intake of retinol on selected clinical and laboratory indexes. Am. J. Clin. Nutr. 1999, 69, 937–943. [CrossRef] [PubMed]
24. Binkley, N.; Krueger, D. Hypervitaminosis a and bone. Nutr. Rev. 2000, 58, 138–144. [CrossRef] [PubMed]
25. Baxmann, A.C.; De OG Mendonca, C.; Heilberg, I.P. Effect of vitamin C supplements on urinary oxalate and ph in calcium stone-forming patients. Kidney Int. 2003, 63, 1066–1071. [CrossRef] [PubMed]
26. Moyad, M.; Lee, J. The Supplement Handbook: A Trusted Expert’s Guide to What Works & What’s Worthless for More Than 100 Conditions; Rodale Books: Emmaus, PA, USA, 2014.
27. Clayman, R.V. Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. J. Urol. 2005, 173, 478–479. [CrossRef]
28. Lee, D.-H.; Folsom, A.R.; Harnack, L.; Halliwell, B.; Jacobs, D.R., Jr. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am. J. Clin. Nutr. 2004, 80, 1194–1200. [CrossRef] [PubMed]
29. Gerster. High-dose vitamin C: A risk for persons with high iron stores? Int. J. Vitam. Nutr. Res. 1999, 69, 67–82. [CrossRef] [PubMed]
30. Pavlatou, M.G.; Papastamataki, M.; Apostolakou, F.; Papassotiriou, I.; Tentolouris, N. FORT and FORD: Two simple and rapid assays in the evaluation of oxidative stress in patients with type 2 diabetes mellitus. Metabolism 2009, 58, 1657–1662. [CrossRef] [PubMed]
31. Klein, E.A.; Thompson, I.; Tangen, C.M.; Lucia, M.S.; Goodman, P.;Ford, L.G.; Parnes, H.L.; Gaziano, J.M.; Karp, D.D. Vitamin E and the risk of prostate cancer: Updated results of the selenium and vitamin E cancer prevention trial (select). JAMA 2012, 306, 1549–1556.
32. Schürks, M.; Glynn, R.J.; Rist, P.M.; Tzourio, C.; Kurth, T. Effects of vitamin E on stroke subtypes: Meta-analysis of randomised controlled trials. BMJ 2010, 341, c5702. [CrossRef] [PubMed]
33. Boskovic, R.; Gargaun, L.; Oren, D.; Djulus, J.; Koren, G. Pregnancy outcome following high doses of vitamin E supplementation. Reprod. Toxicol. 2005, 20, 85–88. [CrossRef] [PubMed]
34. Albanes, D.; Heinonen, O.P.; Taylor, P.R.; Virtamo, J.; Edwards, B.K.; Rautalahti, M.; Hartman, A.M.; Palmgren, J.; Freedman, L.S.; Haapakoski, J. A-tocopherol and β-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: Effects of base-line characteristics and study compliance. J. Natl. Cancer Inst. 1996, 88, 1560–1570.
35. Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 1994, 330, 1029–1035. [CrossRef] [PubMed]
36. Cassileth, B.R.; Lucarelli, C.D. Herb-Drug Interactions in Oncology; PMPH-USA: Beijing, China, 2003.
37. Omenn, G.S.; Goodman, G.E.; Thornquist, M.D.; Balmes, J.; Cullen, M.R.; Glass, A.; Keogh, J.P.; Meyskens, F.L., Jr.; Valanis, B.; Williams, J.H., Jr. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 1996, 334, 1150–1155. [CrossRef] [PubMed]
38. Capper, M.J.; Wright, G.S.A.; Barbieri, L.; Luchinat, E.; Mercatelli, E.; McAlary, L.; Yerbury, J.J.; O’Neill, P.M.; Antonyuk, S.V.; Banci, L.; et al. The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation. Nat. Commun. 2018, 9, 1693. [CrossRef] [PubMed]
39. Fahey, J.W.; Talalay, P. Antioxidant functions of sulforaphane: A potent inducer of phase II detoxication enzymes. Food Chem. Toxicol. 1999, 37, 973–979. [CrossRef]
40. Kensler, T.W.; Davidson, N.E.; Groopman, J.D.; Roebuck, B.D.; Prochaska, H.J.; Talalay, P. Chemoprotection by inducers of electrophile detoxication enzymes. Basic Life Sci. 1993, 61, 127–136. [PubMed]
41. He, C.H.; Gong, P.; Hu, B.; Stewart, D.; Choi, M.E.; Choi, A.M.; Alam, J. Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein. Implication for heme oxygenase-1 gene regulation. J. Biol. Chem. 2001, 276, 20858–20865.
42. Shih, A.Y.; Imbeault, S.; Barakauskas, V.; Erb, H.; Jiang, L.; Li, P.; Murphy, T.H. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J. Biol. Chem. 2005, 280, 22925–22936. [CrossRef] [PubMed]
43. Baird, L.; Dinkova-Kostova, A.T. The cytoprotective role of the Keap1-Nrf2 pathway. Arch. Toxicol. 2011, 85, 241–272. [CrossRef] [PubMed]
44. Holmström, K.M.; Kostov, R.V.; Dinkova-Kostova, A.T. The multifaceted role of Nrf2 in mitochondrial function. Curr. Opin. Toxicol. 2016, 1, 80–91.
45. Deponte, M. The incomplete glutathione puzzle: Just guessing at numbers and figures? Antioxid. Redox Signal. 2017, 27, 1130–1161. [CrossRef] [PubMed]
46. Velu, C.S.; Niture, S.K.; Doneanu, C.E.; Pattabiraman, N.; Srivenugopal, K.S. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry 2007, 46, 7765–7780. [CrossRef] [PubMed]
47. Yang, W.S.; SriRamaratnam, R.; Welsch, M.E.; Shimada, K.; Skouta, R.; Viswanathan, V.S.; Cheah, J.H.; Clemons, P.A.; Shamji, A.F.; Clish, C.B.; et al. Regulation of ferroptotic cancer cell death by gpx4. Cell 2014, 156, 317–331. [CrossRef] [PubMed]
48. Tung, M.-C.; Lin, P.-L.; Wang, Y.-C.; He, T.-Y.; Lee, M.-C.; Yeh, S.-D.; Chen, C.-Y.; Lee, H. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2. Oncotarget 2015, 6, 41692–41705. [CrossRef] [PubMed]
49. DeNicola, G.M.; Karreth, F.A.; Humpton, T.J.; Gopinathan, A.; Wei, C.; Frese, K.; Mangal, D.; Yu, K.H.; Yeo, C.J.; Calhoun, E.S.; et al. Oncogene-induced Nrf2 transcription promotes ros detoxification and tumorigenesis. Nature 2011, 475, 106–109. [CrossRef] [PubMed]
50. Zhang, C.; Wang, H.J.; Bao, Q.C.; Wang, L.; Guo, T.K.; Chen, W.L.; Xu, L.L.; Zhou, H.S.; Bian, J.L.; Yang, Y.R.; et al. NRF2 promotes breast cancer cell proliferation and metastasis by increasing rhoa/rock pathway signal transduction. Oncotarget 2016, 7, 73593. [CrossRef] [PubMed]
51. Jeong, Y.; Hoang, N.T.; Lovejoy, A.; Stehr, H.; Newman, A.M.; Gentles, A.J.; Kong, W.; Truong, D.; Martin, S.; Chaudhuri, A.; Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance. Cancer Discov. 2016, 7, 86–101.
52. Jiang, T.; Chen, N.; Zhao, F.; Wang, X.J.; Kong, B.; Zheng, W.; Zhang, D.D. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010, 70, 5486–5496. [CrossRef] [PubMed]
53. Hino, R.; Uozaki, H.; Murakami, N.; Ushiku, T.; Shinozaki, A.; Ishikawa, S.; Morikawa, T.; Nakaya, T.; Sakatani, T.; Takada, K.; et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 2009, 69, 2766–2774. [CrossRef] [PubMed]
54. Mishra, M.V.; Bisht, K.S.; Sun, L.; Muldoon-Jacobs, K.; Awwad, R.; Kaushal, A.; Nguyen, P.; Huang, L.; Pennington, J.D.; Markovina, S.; et al. DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells. Mol. Cancer Res. 2008, 6, 243–249. [CrossRef] [PubMed]
55. Bonner, M.Y.; Arbiser, J.L. The antioxidant paradox: What are antioxidants and how should they be used in a therapeutic context for cancer. Future Med. Chem. 2014, 6, 1413–1422. [CrossRef] [PubMed]
56. Block, K.I.; Koch, A.C.; Mead, M.N.; Tothy, P.K.; Newman, R.A.; Gyllenhaal, C. Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials. Int. J. Cancer 2008, 123, 1227–1239. [CrossRef] [PubMed]
57. Yasueda, A.; Urushima, H.; Ito, T. Efficacy and interaction of antioxidant supplements as adjuvant therapy in cancer treatment: A systematic review. Integr. Cancer Ther. 2016, 15, 17–39. [CrossRef] [PubMed]
58. Yan, L.J. Positive oxidative stress in aging and aging-related disease tolerance. Redox Biol. 2014, 2, 165–169. [CrossRef] [PubMed]
59. Powers, S.K.; Radak, Z.; Ji, L.L. Exercise-induced oxidative stress: Past, present and future. J. Physiol. 2016, 594, 5081–5092. [CrossRef] [PubMed]
60. Gomez-Cabrera, M.C.; Salvador-Pascual, A.; Cabo, H.; Ferrando, B.; Viña, J. Redox modulation of mitochondriogenesis in exercise. Does antioxidant supplementation blunt the benefits of exercise training? Free Radic. Biol. Med. 2015, 86, 37–46. [CrossRef] [PubMed]
61. Pinterić, M.; Podgorski, I.I.; Sobočanec, S.; Popović Hadžija, M.; Paradžik, M.; Dekanić, A.; Marinović, M.; Halasz, M.; Belužić, R.; Davidović, G.; et al. De novo expression of transfected sirtuin 3 enhances susceptibility of human MCF-7 breast cancer cells to hyperoxia treatment. Free Radic. Res. 2018, 52, 672–684. [CrossRef] [PubMed]
62. Akamata, K.; Wei, J.; Bhattacharyya, M.; Cheresh, P.; Bonner, M.Y.; Arbiser, J.L.; Raparia, K.; Gupta, M.P.; Kamp, D.W.; Varga, J. SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. Oncotarget 2016, 7, 69321–69336. [CrossRef] [PubMed]
63. Pillai, V.B.; Samant, S.; Sundaresan, N.R.; Raghuraman, H.; Kim, G.; Bonner, M.Y.; Arbiser, J.L.; Walker, D.I.; Jones, D.P.; Gius, D.; et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial sirt3. Nat. Commun. 2015, 6, 6656. [CrossRef] [PubMed]
64. Tseng, A.H.; Shieh, S.S.; Wang, D.L. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. Free Radic. Biol. Med. 2013, 63, 222–234. [CrossRef] [PubMed]